Research progress in pharmacological effects of Erigeron breviscapus and its active ingredients for treatment of Alzheimer's disease.
10.19540/j.cnki.cjcmm.20200717.602
- Author:
Yuan-Zhu PU
1
;
Can SU
2
Author Information
1. School of Chinese Materia Medica, Yunnan University of Chinese Medicine Kunming 650500, China.
2. Yunnan Provincial Academy of Science and Technology Kunming 650051, China.
- Publication Type:Systematic Review
- Keywords:
Alzheimer′s disease;
Erigeron breviscapus;
caffeoylquinic acid;
pharmacological effects;
scutellarin
- MeSH:
Alzheimer Disease;
Amyloid beta-Peptides;
Erigeron;
Humans;
Neurodegenerative Diseases
- From:
China Journal of Chinese Materia Medica
2020;45(23):5650-5657
- CountryChina
- Language:Chinese
-
Abstract:
Alzheimer's disease(AD) is a neurodegenerative disease that has no effective drug to cure it. Studies in several AD models have shown that Erigeron breviscapus and its active ingredients(scutellarin and caffeoylquinic acid) could improve/enhance the learning and memory ability, and the mechanisms are associated with inhibiting amyloid β(Aβ) production, aggregation, fibrosis and Aβ neurotoxicity toxicity, regulating cholinergic nervous system, inhibiting oxidative stress and inflammation, inhibiting tau hyperphosphorylation, improving mitochondrial function, and resisting neuronal apoptosis. This article systematically reviewed the research progress of E. breviscapus and its active ingredients for treatment of AD in AD models, in the expectation of providing references for further development of E. breviscapus's medicinal potential.
